Market Currents

Delcath (DCTH) plummets 15.3% after saying that the FDA has accepted its Chemosat delivery...

Monday, October 15, 2012, 9:59 AM ET
Delcath (DCTH) plummets 15.3% after saying that the FDA has accepted its Chemosat delivery system to treat a form of liver cancer for a standard review and not a priority one, as the company requested. That means that the agency has up to ten months to decide whether to approve the Chemosat system rather than six, as per a priority assessment. (PR)

This Market Current was sent to 2,477 people who get email alerts on DCTH.

Get email alerts on DCTH »

Share this Market Current

Short URL:

Track new comments on this story

This news story has 3 comments:

Grassy Comments (3)

its not a big deal - they dont even really want approval for the Chemost 1 system - its system 2 they are after - this may slow down cash flow by one quarter - Green99

15 Oct 2012, 10:05 AM Reply Like

Gary Jakacky Comments (1832)

Well Snoop doggy dogg! The technology that DCTH uses on liver cancer in humans has been tried for years on doggs (and catts) over at WOOF, the old VCA Antech veterinary company. Heard about any poochie miracle cures?

15 Oct 2012, 10:05 AM Reply Like

grube Comments (3)

Why would the FDA do this when there as so many people who can use this treatment to prolong their lives? This just doesn't make any sense to me. Thay are approved in the EU and a using this product in several countries yet can get this done in our own country. I guess this is our government at its very best or its worst.

15 Oct 2012, 10:10 AM Reply Like

LATEST|

TODAY SO FAR|

YESTERDAY

Other date

DJIA (DIA) S&P 500 (SPY)